Avid Bioservices Inc (CDMO): UCLA’s Dr. Pojen Chen: active in C...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	72
Posts	4827
Boards Moderated	0
Alias Born	01/24/2004

cjgaddy

Re: None

Saturday, 12/29/2007 9:40:21 PM

Saturday, December 29, 2007 9:40:21 PM

UCLA’s Dr. Pojen Chen: active in CHAVI/Duke/Haynes HIV studies; added to Peregrine’s SRB list on 12-18-07…

CHAVI Y03 FIRST QTR. PROGRESS REPORT – EXEC. SUMMARY, SEPT. 14, 2007
Barton Haynes, MD, CHAVI Director
Q4-Y02 and Q1-Y03 of CHAVI has been a very productive time. CHAVI continues to make progress in administration of the CHAVI grant… Most importantly, CHAVI is making progress in scientific discoveries to remove roadblocks that impede HIV-1 vaccine development.
... The major scientific goals for year 2 were: . . .
10. Obtain human monoclonal antibodies from acutely infected HIV-1 patients and from autoimmune disease patients and determine their ability to neutralize HIV-1.
Report: James Robinson [Tulane], David Montefiori [Duke], George Shaw [U-Alabama] and Lynn Morris [NICD] comprise our team that is evaluating the specificities of the first neutralizing antibodies produced in acute HIV-1 infection, and have raised monoclonal antibodies that represent these antibodies. Tony Moody [Duke, Dir., Bcell Immunology Lab] and Bart Haynes [Duke, Dir. of Human Vaccine Institute] lead the studies in autoimmune disease patients, and with Pojen Chen at UCLA, have found human mabs from SLE and primary antiphospholipid syndrome patients that broadly neutralize HIV-1 primary isolates. The team is working on design of immunogens to safely induce these types of antibodies. This Fall, the B Cell Team will perform a passive antibody protection trial of broadly neutralizing human Mabs in rhesus monkeys to determine if these Mabs can have a protective effect on mucosal challenge of NHP with a SHIV challenge virus. . .
http://www.chavi.org/modules/chavi_reports/index.php?id=17

POJEN P. CHEN JOINS PPHM’S SRB:
PEREGRINE PHARMACEUTICAL'S SCIENTIFIC RESOURCE BOARD (SRB)
. . . 23 members, as of the 12-18-07 website update. 11 additions (in italics)…
CORE TECHNOLOGIES
1. Pojen P. Chen, Ph.D. – Prof. of Medicine, Rheumatology Div., Univ. of Calif. [UCLA] http://tinyurl.com/293xn8 & http://tinyurl.com/2bozbb PMeds: http://tinyurl.com/2evl5k
SRB: http://www.peregrineinc.com/index.php?option=com_content&task=view&id=15&Itemid=29

= = = = = = =
GLOBAL HIV VACCINE ENTERPRISE http://www.hivvaccineenterprise.org
Comprised of 2 “implementation projects”:
1. CHAVI - Center for HIV/AIDS Vaccine Immunology http://www.chavi.org
. . . . . . $300mm over 7 years from NIAID to CHAVI (Dir=B.Haynes).
2. CAVD - Collaboration for AIDS Vaccine Discovery http://www.cavd.org
. . . . . . $287mm over 5 years from BMGF to CAVD ($15mm to B.Haynes).

4-4-07: Duke's B.Haynes DHVI website outlines Thorpe’s Role in the CAVD-gates HIV-Vaccine Initiative: http://tinyurl.com/23v4xc
”Philip Thorpe is determining the role of lipid binding of anti-HIV antibodies & anti-PS autoantibodies to protection from HIV infection. With Philip Thorpe, studies are planned to determine if anti-PS antibodies can prevent infection or early viral destruction of the immune system in acute SIV infection.”
...8-2007: Global HIV Vaccine Enterprise Report of Activities 2005-2007 (65-pg PDF): http://tinyurl.com/3xtk3n
...4-24-07: GATES-FOUNDATION rep's lecture at U-WASH lists P.Thorpe on CAVD grants map: http://tinyurl.com/yqqk6r
...1-27-07: Dr. Haynes (Chavi Dir.), ‘Center for HIV/AIDS Vaccine Immunology’ report (50-pg PDF): http://tinyurl.com/2ah5fy